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The number of patients with obstructive airway disease has been increasing worldwide. The delivery of aerosol drugs 
through the respiratory system has become a central element in the management of asthma and chronic obstructive 
pulmonary disease (COPD). The aim of this study was to validate and apply a stochastic whole respiratory tract deposition 
model in order to characterize airway deposition distribution of two different marketed drugs delivered in form of dry 
powders (Seretide® Diskus® and Symbicort® Turbuhaler®), and to analyze the possibility of computerized drug delivery 
optimization in the future. Spirometry measurements on 17 adult volunteers have been performed. Relationships between 
breathing parameters measured during diagnostic spirometry and those characterising breathing during drug administration 
through Diskus® and Turbuhaler® inhalers have been derived. The doses deposited in different anatomical regions of the 
respiratory tract and airway generation number specific deposited doses have been computed for the participating 
individuals based on both mass median aerodynamic diameter (MMAD) and detailed size distribution of the two drugs. 
Although regional deposited doses were not very different in the two cases, airway generation number specific deposition 
distributions were sensitive to this input parameter, indicating the need for the whole size distribution when modelling 
airway deposition of aerosol drugs. Significant intersubject variability in terms of oropharyngeal, bronchial and acinar 
deposited doses have been found. The results highlight the necessity for and open the possibility of simulation assisted 
customized drug selection in the future. 
 







As an unwanted tendency, the number of patients with 
obstructive airway diseases has been increasing worldwide. 
According to recent estimation, solely asthma affects about 
300 million people in the world and every year around 
255,000 people are losing their lives around the world 
because of this disease (Saillaja, 2014). By the same token, 
the prevalence of chronic obstructive pulmonary disease 
(COPD) is also sharply increasing and the World Health 
Organization (WHO) predicts that COPD will be the third 
leading cause of death by 2030 (World Health Statistics, 
2008). The increased mortality is mainly driven by the 
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other common causes of death (e.g., ischemic heart disease, 
infectious diseases), and aging of the world population 
(GOLD, 2015). The increasing number of asthmatic and 
COPD patients is also associated with enormous healthcare 
expenditures. Besides direct costs of hospitalization and 
medications, indirect costs mainly due to work and school 
loss and disability are also significant. At the same time, 
the rise of obstructive pulmonary diseases has triggered 
intensive research across the world. Most of the researchers 
are focusing on understanding the pathophysiology of these 
diseases and on finding a cure for it, but there is also 
research effort directed towards increasing patient compliance 
with medications. In the past 50–60 years, the delivery of 
aerosol drugs through the respiratory system has become a 
central element in the management of the above diseases 
(Marek et al., 2013). In spite of the large amounts of money 
invested in the development of new drugs, but much less in 
inhaler development, there are several unsolved problems 
that lower the efficiency of current asthma and COPD 
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improper inhaler/drug selection, lack of exhaustive patient 
education, the inadequate use of the inhaler, inaptness of 
producing the inhalation flow rate threshold in case of dry 
powder inhalers (DPIs) or incapability to synchronize the 
breath with the actuation of the drug in case of pressurized 
metered dose inhalers (pMDIs). Another category of reasons 
leading to inefficient drug delivery and ultimately to an 
inefficient treatment is connected to the improper selection 
of drug and/or breathing parameters when inhaling the drug. 
Knowledge of the most relevant effects and parameters 
influencing airway deposition of therapeutic aerosols and 
knowledge of deposition distribution itself are essential for 
the assessment of their effect and a prerequisite for the 
optimization of drug delivery. Airway deposition of the 
inhaled therapeutic aerosols is commonly studied in vivo 
by gamma scintigraphy (Marek et al., 2013). The location 
of the radiolabelled aerosols deposited in the airways after 
their inhalation can be visualised by gamma cameras. Based 
on these images information on the quantity and spatial 
distribution of the deposited particles within the respiratory 
system can be obtained (Borgström et al., 1994; Hirst et 
al.; 2001; Warren et al., 2002; Pitcairn et al., 2005, among 
others). However, the resolution of such images is limited 
and information is lost also because of the two dimensional 
mapping of the realistic three dimensional deposition patterns. 
For instance, due to the complex morphological structure of 
the airways, the spots in the central zone of a 2D scintigraphy 
image can represent not only radiolabelled aerosols deposited 
in the large bronchi, but also in the peripheral airways. 
Realistic spatial distribution can be better reconstructed by 
using rotating gamma cameras (SPECT, single photon 
emission computed tomography), though this measurement 
takes longer and deposited particles can move meanwhile 
due to mucociliary clearance. Positron emission tomography 
(PET) holds the advantage of short exposure time and low 
amount of labelling nuclides; however, it operates with short-
lived isotopes requiring the existence of an accelerator 
nearby. By combining SPECT and PET with CT (computed 
tomography) imaging information on anatomy and deposition 
can be superimposed (Greenblatt et al., 2015). Other 
innovative and promising visualisation techniques, such as 
endo-bronchial ultrasound (EBUS) or optical coherence 
tomography (OCT) are presently under development, 
validation and standardization (Conway, 2012). An alternative 
way of studying the deposition-distribution of aerosol 
drugs within the airways avoiding the ethical problems and 
technical barriers of in vivo studies is to perform computer 
modelling. In addition, computer simulations are non-
invasive, cost effective and repeatable. 
An increasing number of studies modelling airway 
transport and deposition of aerosol drugs are available in 
the open literature. However, most of these studies are 
focusing either on general aspects of airway deposition of 
inhaled therapeutic particles (e.g., Finlay, 2001; Farkas et 
al., 2006) or on phenomena specific to inhalation of aerosol 
drugs (e.g., hygroscopicity or electric charge effects; 
Asgharian, 2004; Xi et al., 2014), but there is a lack of 
works modelling the deposition of concrete available drugs 
based on realistic measured breathing patterns and specific 
drug size distributions. 
The aim of this study was to apply state of the art 
computational methods in order to characterize the deposition 
distribution of two marketed aerosol drugs in the respiratory 
system and to assess the possibility of future computer 
assisted personalized drug choice and delivery. As a result 
of such an optimised aerosol drug administration the chances 
of unwanted side-effects would be minimised and the 




In this study sample simulations on airway transport and 
deposition of two dry powder inhalation drugs commonly 
used in asthma and COPD therapy, namely Seretide® Diskus® 
(fluticasone propionate/salmeterol xinafoate) and Symbicort® 
Turbuhaler® (budesonide/formoterol fumarate dihydrate), 
have been performed. In addition to their large scale use, 
there is a relatively large amount of data available in the 
open literature about these two inhalation corticosteroid – 
long-acting β2-agonist (ICS-LABA) combination drugs. 
Some of these data represent key inputs for appropriate 
modelling of drug deposition. It is worth noting that the 
primary objective of the study was to demonstrate the 
feasibility of validated numerical models to study and 
optimize of aerosol drug delivery, rather than deciding 
which of the two drugs is more appropriate in general. 
To simulate realistic scenarios, spirometry measurements 
on 17 healthy adult volunteers have been performed with a 
PDD-301/sh Piston type spirometer. Volunteers selected 
for the study were aged 27–57 years (mean, 36 years). Mean 
weight and height was 73.5 kg (range, 59–109 kg) and 
177.7 cm (range, 167–188 cm), respectively. The volunteers 
had normal lung function with forced vital capacity (FVC) 
and forced expiratory volume in the first second (FEV1) > 
80% of predicted. Since FEV1 and its ratio to the forced 
vital capacity (FEV1/FVC) of healthy individuals and well 
controlled mild asthmatics do not differ, present results can 
be considered as characteristic of such patients. At the 
beginning, normal spirometry tests were performed on the 
volunteers without any inhaler. After these measurements, 
the volunteers were instructed about the use of inhalers and 
about the desired mode of breathing. They were asked to 
inhale strongly after a forced expiration, hold their breath 
about ten seconds, and then exhale slowly. The spirometer 
was inserted between the mouth of the volunteers and the 
inhaler. Inhalation was performed through the inhaler, which 
was then removed during breath-hold. Each individual 
inhaled through both inhalers included in this study (Diskus® 
and Turbuhaler®). The inhalers were not filled with active 
drug. Since flow resistance of an empty inhaler is quite 
similar to the resistance of the filled device, this could not 
alter the accurateness of flow metric measurements. The 
recorded parameters needed for the modelling were 
inspiratory vital capacity (IVC), peak inspiratory flow (PIF), 
inhalation time, breath-hold time and exhalation time. The 
functional residual capacity (FRC) values were weight, 
height and gender specific reference values derived from 
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The simulations were performed by the newest version 
of a whole lung deposition model, named Stochastic Lung 
Deposition Model. The model was originally developed by 
Koblinger and Hofmann (1985) and continuously extended 
during the last three decades (Koblinger and Hofmann, 
1990; Hofmann and Koblinger, 1992; Hofmann et al., 2002; 
Hofmann et al., 2006). The model computes the fraction of 
the particles deposited in each anatomical region of the 
airway system and it also yields the deposition fraction as 
a function of airway generation number. By definition, 
deposition fraction is the ratio of the number of particles 
deposited in a certain airway segment to the number of 
inhaled particles. By the same token, deposition mass (or 
dose) fraction is the ratio of the deposited mass (or dose) in 
the region of interest to the inhaled mass (or dose). 
Computation of upper airway deposition fraction is based 
on empirical relationships incorporated into the model 
(Stahlhofen et al., 1989). Particle transport and deposition 
within the lung is modelled by tracking each particle in a 
stochastic asymmetric structure. The variability of airway 
diameters, lengths, branching and gravity angles, constrained 
by correlations among some of these parameters, is described 
mathematically by probability density- and correlation 
functions. In this model the bronchial airways contain both 
bronchi and bronchioli, starting from the trachea (as 
generation 1) and ending with the terminal bronchioles. 
The airway generation number of terminal bronchioles 
varies from 12 to 21. The airway structure is selected by 
Monte Carlo techniques from the empirical distributions of 
geometric parameters. The acinar airways start with four 
generations of respiratory bronchioles and contain the alveolar 
ducts, the alveoli and the alveolar sacs. The maximum 
airway generation number, corresponding to alveolar sacs, 
varies between 18 and 33. Deposition of particles in a 
given airway generation is computed by analytical equations. 
Inertial impaction, gravitational settling and Brownian 
diffusion are considered as deposition mechanisms. Due to 
the variability of the airway geometry and related flows, 
particle deposition may vary along different paths. Thus, 
penetration probabilities to a given airway generation, i.e., 
the probability of inhaled drug particles to reach that airway 
generation, exhibits significant fluctuations, depending on the 
individual history of each particle in upstream airways. By 
simulating the random paths of many particles, typically 
one hundred thousand, statistical means can be calculated 
for total, regional and generational deposition. The main 
breathing parameters and aerosol parameters which serve 




The lung deposition model used in this study has been 
validated against the results of both in vitro (deposition 
measurements in airway casts) and in vivo (using gamma 
scintigraphy) airway deposition measurements of different 
types of aerosols. Validation of the model for medical 
aerosols emitted by pMDI has been recently performed 
(Jókay et al., 2015). In the current study we present a 
comparison of simulation results with the outcomes of a 
series of in vivo deposition measurements with aerosol 
drugs emitted by DPI. One of the most studied cases in the 
literature is the deposition of budesonide from Turbuhaler® 
by means of scintigraphy. An extensive survey of the 
literature demonstrated that lung deposition of budesonide 
measured by different investigators ranged between 14.2% 
(Newman et al., 1989) and 32% (Thorsson et al., 1994) of 
the metered dose. The notable differences can be due to the 
inherent dosing characteristics of Turbuhaler®, the employed 
radiolabelling method, the different patient groups and 
breathing patterns (different inhalation flow rates and 
breath-hold times). In this work, we selected some of those 
in vivo studies with available information on each parameter 
necessary for the simulations (Borgström et al., 1994; Hirst 
et al.; 2001; Warren et al., 2002; Pitcairn et al., 2005). The 
results of the above works and our corresponding simulation 
results are depicted in Fig. 1. The doses deposited in the 
oropharyngeal region and in the lungs are expressed as a 
function of the metered dose. The size distributions of the 
drug and the breathing parameters during drug intake needed 
for the simulations were derived from the same papers. 
Fig. 1 demonstrates that our simulation results in terms of 
extrathoracic and lung deposition percentages are in line with 
the previously published results of experimental deposition 
measurements. The differences are usually within the
 
Table 1. Breathing parameters and aerosol characteristics representing the primary inputs of the deposition model. 
Breathing parameters 





breathing mode (mouth/nose) 
particle inhalation mode (uniform/bolus) 
Aerosol parameters 
particle density 
size distribution type (monodisperse or polydisperse) 
particle size (if monodisperse, or MMAD if polydisperse) 
number of size intervals (if polydisperse) 
weights for each interval (if polydisperse) 
particle shape (spherical or not) 
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Fig. 1. Comparison of airway deposition simulation results with the outcome of scintigraphic deposition measurements of 
budesonide emitted by Turbuhaler® performed by four different investigators. The dose deposited in different anatomical 
regions is expressed as a percentage of the metered dose. The measured dose values are averages of the measurements on 
more subjects, while the error bars represent the dose range of the individual measurements (Pitcairn et al., 2005) or 
standard deviation (Borgström et al., 1994; Hirst et al., 2001; Warren et al., 2002). 
 
intersubject variability of the results of the measurements. 
The best agreement is with the measured deposition results 
of Borgström et al. (1994). Since these in vivo measurements 
were compared also with in vitro measurements (Delvadia 
et al., 2013) and good agreement was found, it can be 
stated that present simulation results are in line with the 
results of both in vivo and in vitro deposition experiments. 
The good matching indicates that our model is accurate 
enough and suitable for the simulation of aerosol drug 
deposition within the airways. 
 
RESULTS AND DISCUSSION 
 
Airway deposition distribution of any kind of inhaled 
aerosol particles depends on aerosol characteristics, airway 
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of aerosol drugs is a special case from many points of 
view. First of all, contrary to the environmental aerosols 
which are inhaled predominantly by nose breathing (except 
during heavy physical exercise; ICRP66, 1994), medical 
aerosols follow the oropharyngeal route. Since the nose is 
a better aerosol filter than the mouth, aerosol drugs have a 
better chance to reach the lung. Other parameters of the 
exposure are the velocity of the particles/droplets, their 
concentration and spatio-temporal distribution. While the 
velocity of dry powders can be approximated to be equal 
to the speed of the inhaled air, the initial velocity of 
droplets is characteristic of the pMDI device they are 
emitted from. Generally, there is variability in terms of 
emitted droplet velocity, drug emission angle, concentration 
of the emitted particles and bolus length among different 
pMDIs. All these particularities should be carefully taken 
into account when modelling the fate of the inhaled 
therapeutic aerosols. In this study we restrict our analysis 
to the case of DPIs, thus we assume that velocity and entrance 
angle of the particles entering the respiratory system is similar 
to the speed and orientation profile of the inhaled air. 
Variability of breathing pattern among different healthy 
individuals leads to an intersubject variability for particle 
deposition (Majid et al., 2011). The scatter of breathing 
parameter values becomes even more pronounced in the 
case of patients with obstructive lung diseases. Breathing 
capabilities of each individual should be accounted for when 
choosing the appropriate aerosol drug and inhaler. Since 
patients are diagnosed primarily based on spirometry tests, 
actually this information is available at the moment of the 
prescription of the drug. However, inhalers have specific 
resistance and the breathing parameter values acquired 
during a normal lung function test are different from those 
recorded during the inhalation of aerosol drugs. Left panel 
of Fig. 2 shows the inspiratory vital capacity measured 
when inhaling through Seretide® Diskus® and Symbicort® 
Turbuhaler® inhalation devices as a function of IVC of the 
same individuals derived from standard spirometry tests. On 
the right panel the same relationships for the corresponding 
PIF values are presented. 
Based on Fig. 2 the measured breathing parameter values 
of an individual depend on whether they are acquired 
without an inhalation device (normal spirometry) or they 
are measured when inhaling through an inhaler. On the 
other hand, they also depend on the specific resistance of 
each inhaler. Both plots indicate a higher airflow resistance 
for Turbuhaler® than for Diskus®, which is in line with the 
outcome of previous studies (Palen, 2003; Melani et al., 
2005). For an accurate and reliable numerical modelling 
the knowledge of parameter values characterizing breathing 
when inhaling through the inhalation device is of key 
importance. From the perspective of disease management 
it is also of great importance to know whether a patient is 
able to apply a correct breathing mode or not. Dry powder 
inhalers usually require a minimum inhalation flow rate to 
emit a considerable amount of fine particles with chances 
to reach the intrathoracic airways. Since standard spirometry 
data alone are not sufficient to decide whether a patient is able 
to efficiently use a given inhaler or not, the establishment of 
relationships similar to the ones deduced in Fig. 2 for all 
the marketed DPIs would be necessary. In order to establish 
statistically relevant correlations, these relationships 
should rely on measurements on a much higher number of 
individuals (and possibly more measurements for the same 
patient) than in the present study, preferably grouped into 
types and levels of diseases, categories of ages and genders. 
Airway geometry is a major determinant of aerosol drug 
deposition. Besides the age and gender dependence of the 
geometry and the intersubject and other types of anatomical 
variabilities, there are significant morphological and 
morphometrical differences between healthy and diseased 
airways. The modified airway geometry of asthmatics and 
COPD patients may influence the fate of the inhaled 
medication. Martonen et al. (2003) have shown that 
deposition efficiency of the inhaled particles was strongly 
dependent on the degree of the reduction of airway lumen. 
The deposited fraction and both regional (Horváth et al., 
2011) and local (Farkas et al., 2006; Farkas and Balásházy,
 
  
Fig. 2. IVC values measured during inhalation through Seretide® Diskus® and Symbicort® Turbuhaler® as a function of 
spirometric IVC values of the same volunteers (left panel), and PIF values measured during inhalation through Seretide® 
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2007) distribution of the deposited particles changes when 
the airways are constricted. We have also adapted our lung 
deposition model presented in the Methods section to the case 
of narrowed airways (see Horváth et al., 2011), however, in 
this work we studied the deposition of aerosol drugs only 
in healthy individuals. The results are applicable also to 
drug delivery in the case of well controlled asthmatics. 
The size of a particle is the dominant parameter influencing 
its transport and deposition in the airways. Aerosol drugs 
are usually characterized by their mass median aerodynamic 
diameter (MMAD) and the corresponding geometric standard 
deviation (GSD). In many cases fine particle fraction (FPF, 
which is the fraction of the particles with diameters smaller 
than 5 µm) is also provided, indicating the fraction of 
particles potentially reaching the lung. Although these 
parameters provide useful information on the size of the 
particles, for an accurate modelling the knowledge of the 
whole size distribution is needed. It is worth noting that 
size distribution and consequently MMAD and FPF values 
characterizing the drugs emitted by DPIs depend on 
inhalation flow rate. Kamin et al. (2002) have demonstrated 
that besides flow rate, air acceleration can also influence 
these parameters. The dependence of MMAD on PIF in 
case of Seretide® Diskus® and Symbicort® Turbuhaler® has 
been quantified by Tarsin et al. (2006). However, the flow 
rate dependence of the whole distribution of the marketed 
drugs is not available in the published literature. In case of 
Seretide® Diskus® and Symbicort® Turbuhaler® the particle 
size profile has been determined by various methods, e.g., 
by impactor (Johal et al., 2013), by aerodynamic particle 
sizer spectrometer (Tamura et al., 2012) or by liquid 
chromatography (Assi et al., 2006), but only at about 30 
L min–1 and 60 L min–1 flow rates. Therefore, for the 
simulations we selected those volunteers whose PIF was 
around 60 L min–1. Average PIF of these eight volunteers 
was 62.48 L min–1 (range, 52.2–67.8), while the mean flow 
rate averaged over the eight individuals was 52.6 L min–1 
(range, 50.4–62.5). Measured size distributions and MMAD 
values characterizing Seretide® Diskus® and Symbicort® 
Turbuhaler® were adopted from Johal et al. (2013). Left 
panel of Fig. 3 depicts the computed deposition fractions as 
a percentage of the metered dose (specified in the Summary 
of Product Characteristics of each drug) in the extrathoracic 
airways and in the lung, if MMAD (3.8 µm for Seretide® 
and 2.5 µm for Symbicort®) or the size-distributions of the 
particles emitted by Diskus® and Turbuhaler® inhalation 
devices are taken into account as input data. The higher 
upper airway deposited dose of Seretide® compared to 
Symbicort® is due to the higher number of large particles in 
Seretide®, which deposit by impaction. Since more particles 
of this drug are filtered by the mouth-throat region, lung 
deposition is lower in case of Seretide®. By the same 
token, based on the left panel of the figure the regional 
deposition percentages are not very different when MMAD 
or size distribution is considered. Due to the nonlinear 
dependency of upper airway deposition efficiency on 
particle diameter (Cheng, 2003; Grgic et al., 2004) even a 
symmetrical size distribution (around MMAD) yields a 
higher extrathoracic deposition than the MMAD based 
deposition value. Size distribution measurements revealed 
that while particles from Symbicort® Turbuhaler® can be 
characterized by a relatively narrow monomodal distribution, 
Seretide® particles are more polydisperse with a more 
elongated shape of the right tail of their size distribution 
curve (Tamura et al., 2012). This difference is translated 
into a higher gap between the computed upper airway doses 
based on MMAD and size distribution in the case of this 
later drug (Seretide®). When studying the distribution of 
the deposition within an anatomical region (e.g., lung) the 
use of exact size distributions instead of MMADs becomes 
more important. Right panel of Fig. 3 depicts the airway 
generation number specific dose deposition for Seretide® 
Diskus® and Symbicort® Turbuhaler®. It is worth noting that 
such detailed information on the spatial distribution of the 
deposited drug cannot be obtained with scintigraphy. The 
figure demonstrates that although the character of deposition 
curves corresponding to MMAD and size distribution cases 
is quite similar, there are notable differences at the acinar 
peak (around airway generation 21). 
Nevertheless, deposition in the conductive airways seems 
to be well described by simulations based on MMAD. It is 
worth noting that aerosol drugs with a broader size spectrum 
(higher GSD) and highly asymmetrical size distribution 
may yield less appropriate deposition data if only MMAD 
is considered. The relatively good matching in the present 
case enables us to model airway deposition of the two 
selected drugs for all volunteers by considering the change 
of MMAD with inhalation flow rate. Such relationships 
between MMAD and PIF have been derived by Tarsin et 
al. (2006) for both Seretide® and Symbicort®. Fig. 4 
demonstrates the individual regional (extrathoratic and 
different regions of the lung) dose fraction values of Seretide® 
and Symbicort® for the 17 volunteers participating in this 
study. Lung deposition is divided into bronchial (Br) and 
acinar (Ac) deposition and drug deposition in the respiratory 
bronchioles (Brr) is also presented. 
Average values of computed doses deposited in the 
extrathoracic airways (ET, including mouth, pharynx and 
larynx) and in the lung (Br + Ac) depicted in Fig. 4 are 
quite similar to the corresponding values in Fig. 3. However, 
a significant intersubject variability of the deposited doses 
can be found in every distinct region of the respiratory 
system for both studied drugs. This raises the possibility to 
choose between the different drugs if high deposition in a 
certain airway region of a given patient is desired, that is, 
the region is a target area for a given agent with high 
density of receptors. For instance, Haughney et al. (2010) 
emphasized that based on works of Carstairs et al. (1985) 
and Mak and Barnes (1990) large and conductive airways 
(down to about airway generation 16) may be preferred for 
bronchodilators (like the LABA components of Seretide® 
and Symbicort®) because in this part of the airways β2 
receptors are present in conjunction with smooth muscle. 
In the present study for 9 individuals Seretide® yielded 
higher deposition (as a percentage of the metered dose) in 
this region, while deposition of Symbicort® was higher in 
the case of 8 individuals. However, to avoid unwanted side 
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Fig. 3. Regional (left panel) and airway generation number specific (right panel) deposited doses as a percentage of the 
metered dose in case of Seretide® Diskus® and Symbicort® Turbuhaler® if either MMAD or the whole size distribution is 
taken into account. 
 
       
Fig. 4. Calculated individual deposited doses in the extrathoracic (ET), bronchial (Br), acinar (Ac) and respiratory bronchiolar 
(Brr) regions of the airways for Seretide® Diskus® and Symbicort® Turbuhaler® as a percentage of the metered doses. 
 
should be maximized, but also the dose depositing outside 
this zone needs to be minimized. In the present case, the ratio 
of the dose deposited in the large bronchi and bronchioli 
(denoted by Br) to the dose depositing elsewhere within 
the airways (ET+Ac) was higher for Seretide® in 5 cases 
and for Symbicort® in 12 cases. Right panel of Fig. 3 
demonstrates that deposition is the highest in airway 
generations 16–25. Respiratory bronchioles (Brr) fall in this 
interval. For this reason, it is an essential question whether 
Brr is a target area or not. The consideration of this part of 
the airways as target zone for β2 agonist bronchodilators is 
supported by the observation that the relative density of β- 
adrenergic receptors increases with the increase of airway 
generation number (Ikeda et al., 2012). At the same time, 
the amount of smooth muscle is considerably reduced in 
this partly alveolated region of the airways. In our case if 
not only the conductive airways (Br), but also the Brr 
region is targeted, then Seretide® yields higher deposition 
in 7 cases, while Symbicort® in 10 individuals. It is also 
important to note that the location of target zone for the 
ICS component does not coincide with the target area of 
the LABA component of the same combination drug. A 
more uniform lung deposition may be preferred for ICS to 
reach also the small airways (Hamid et al., 1997; Tulic and 
Hamid, 2006). This suggests that the above described 
quantities (the dose deposited in the Br region, the dose 
deposited in the Br region divided by the dose deposited in 
the ET and Ac regions, the dose deposited in the Br and 
Brr regions) may not be the appropriate indicators of the 
efficiency of drug delivery in the case of combination (ICS-
LABA) drugs. Moreover, considering deposition densities 
(deposited dose divided by the surface area of that zone) 
instead of deposited percentage could be a better indicator. 
It falls out of the scope and possibilities of this study to decide 
on the appropriate target zone and on the most suitable 
indicator of aerosol drug delivery efficiency. Nevertheless, 
the above examples demonstrate that once such an indicator 
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only in the characterization of drug deposition, but also in 
helping pulmonologists to choose the appropriate drug and 
device for delivery. Obviously, numerical modelling 
cannot substitute for clinical observation and experience, but 





A stochastic whole respiratory tract deposition model 
has been adapted to the special case of therapeutic aerosols. 
Comparison of the computed deposition doses with the results 
of several in vivo deposition experiments reveals that our 
computer model is suitable for the modeling of airway 
transport and deposition of aerosol drugs. Relationships 
between breathing parameters measured during diagnostic 
spirometry and those characterising breathing during drug 
administration through Diskus® and Turbuhaler® inhalers 
have been derived. These relationships are links between 
the routinely measured lung function data and the breathing 
parameters characterizing the intake of drugs through inhalers 
with specific resistance. These kinds of relationships are 
useful also when deciding whether a patient is able to 
properly use a given inhalation device. Regional deposited 
doses were not very different when MMAD or detailed 
size distribution was considered. However, generation 
number specific deposition distributions were sensitive to 
this input parameter, indicating the need for the whole size 
distribution when modelling airway deposition of aerosol 
drugs. The observed interindividual differences in terms of 
oropharyngeal, bronchial and acinar deposited doses 
highlight the necessity for customized drug selection and 
delivery in the future. Validated numerical models can be a 
powerful tool in assisting the specialists in the selection of 
appropriate drug, device and breathing mode to deliver the 
right amount of the most suitable medication to the right 
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